Accession Number : ADB164109

Title :   Drug Development Against Viral Diseases.

Descriptive Note : Annual rept. 1 Feb 90-31 Jan 91,

Corporate Author : YALE UNIV NEW HAVEN CT SCHOOL OF MEDICINE

Personal Author(s) : Tignor, Gregory H.

Report Date : 01 FEB 1991

Pagination or Media Count : 31

Abstract : Quinolamine (Riker Laboratories, AVS 1018) was eminently promising in the yellow fever virus primate model. Treatment before and after virus infection protected 5 virus inoculated monkeys from disease for 25 days. Two of 3 untreated cynomolgous monkeys infected with the Asibi strain of yellow fever virus died within 5 days of infection. Viremia in treated-monkeys was delayed and markedly reduced. Measurable alpha/beta interferon was present in serum of drug-treated animals weeks after initiating and maintaining drug therapy. Surviving monkeys developed dermal lesions when inoculated with wild-type vaccinia virus. Anti-viral drugs; Vaccinia virus; Yellow fever virus; RA 1.

Descriptors :   *THERAPY, *YELLOW FEVER VIRUS, *VIRUS DISEASES, DRUGS, INTERFERON, LESIONS, MONKEYS, PRIMATES, YELLOW FEVER, INFECTIOUS DISEASES.

Subject Categories : Medicine and Medical Research
      Pharmacology

Distribution Statement : APPROVED FOR PUBLIC RELEASE